A phase II, multicenter, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancer: ALEPRO trial.

Tine Ottenbourgs Toon Van GorpFrédéric KridelkaThaïs BaertHannelore DenysFrédéric SelleInge BaasAnne-Sophie Van RompuyDiether LambrechtsEls Van Nieuwenhuysen

Published in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2024)

NCT05872204.

Keyphrases